Skip to content

The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study

The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06747299
Enrollment
200
Registered
2024-12-24
Start date
2025-01-01
Completion date
2027-12-31
Last updated
2024-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T-NK Cell Lymphoma

Keywords

T-NK cell Lymphoma, PET/CT, Diferential Diagnosis, Efficacy Prediction, Prognosis Prediction

Brief summary

Based on the PET/CT imaging data of patients with T-NK cell lymphoma, machine learning and deep learning methods are used to extract imaging features, establish a T-NK cell lymphoma prediction model, and provide more scientific and accurate prognosis prediction for the clinic.

Detailed description

This study adopts a multicenter retrospective cohort study design,we provided PET/CT of 200 patients with T-NK cell lymphoma as an external validation set for model validation.

Interventions

None listed

Sponsors

West China Hospital
CollaboratorOTHER
Ruijin Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1\. Pathological histology confirmed as T-NK Cell Lymphoma; 2.18F-FDG PET/CT examination before treatment; 3. Using modern best practice treatment options; 4. Complete clinicopathological and follow-up data were obtained.

Exclusion criteria

1. The patient had previously received antitumor therapy; 2. The patient had a history of other tumors; 3. Incomplete clinical information or imaging data; 4. Concomitant other malignant tumors.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation the value of Artificial Intelligence-based 18F-FDG PET/CT of T-NK Cell LymphomaWithin 1 week of enrollment and after 3 months treatmentThe Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma

Secondary

MeasureTime frameDescription
Progress free survival3 yearsProgress free survival
Overall survival3 yearsOverall survival

Countries

China

Contacts

Primary ContactGuo rui Deputy director
gr11734@rjh.com.cn13361860108

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026